Skip to main content

Epstein-Barr Virus Infections

2
Pipeline Programs
2
Companies
4
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Cell Therapy
1100%
+ 1 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
1
cytotoxic t-lymphocytesPhase 22 trials
Active Trials
NCT01945619No Longer Available
NCT03266653Recruiting20Est. Dec 2027
Atara Biotherapeutics
Atara BiotherapeuticsCA - Thousand Oaks
1 program
1
tabelecleucelPhase 2Cell Therapy2 trials
Active Trials
NCT02822495No Longer Available
NCT03769467Terminated12Est. Aug 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Angeles Therapeuticscytotoxic t-lymphocytes
Atara Biotherapeuticstabelecleucel

Clinical Trials (4)

Total enrollment: 32 patients across 4 trials

NCT03266653Angeles Therapeuticscytotoxic t-lymphocytes

EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection

Start: Jul 2020Est. completion: Dec 202720 patients
Phase 2Recruiting
NCT03769467Atara Biotherapeuticstabelecleucel

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Start: Feb 2019Est. completion: Aug 202112 patients
Phase 1/2Terminated
NCT01945619Angeles Therapeuticscytotoxic t-lymphocytes

Allogeneic Virus-Specific Cytotoxic T-Lymphocytes(CTL), Persistent/Recurrent Viral Infection Post-HSCT (EAP CHALLAH)

N/ANo Longer Available
NCT02822495Atara Biotherapeuticstabelecleucel

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

N/ANo Longer Available

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 32 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.